Patients taking Kerendia saw significant reduction in cardiovascular death and hospitalization and urgent visits for heart ...

The US Food and Drug Administration (FDA) has granted 510(k) clearance for Tempus AI’s ECG-Low (ejection fraction) EF ...

Researchers at the German Center for Cardiovascular Research (DZHK) have identified a key molecule involved in a form of ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

The new Tempus software analyzes resting, non-ambulatory 12-lead ECG recordings to detect signs associated with having a low ...

Tempus AI Inc (NASDAQ:TEM) shares are trading higher Wednesday after the company announced that it received 510(k) clearance ...

The approval was supported by data from the randomized, double-blind, placebo-controlled, event-driven phase 3 FINEARTS-HF study.

The era of predictive modeling enhanced with machine learning and artificial intelligence (AI) to aid clinical ...

“Weight loss quality is a new concept….The discussion no longer revolves around the lack of adequate efficacy but rather ...

Following priority review, the U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) for the treatment of ...

NewYork-Presbyterian researchers have developed a deep learning model that increases doctors' abilities to diagnose ...

Wearables and telehealth are teaming up to transform chronic care. This connected model offers real-time data for proactive, ...